Navigation Links
Par Pharmaceutical Halts Shipment of Budesonide Inhalation Suspension
Date:11/20/2008

WOODCLIFF LAKE, N.J., Nov. 20 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. (NYSE: PRX) today announced that the U.S. District Court for the District of New Jersey last night granted AstraZeneca Pharmaceuticals' motion for a temporary restraining order (TRO) halting sales of Teva's generic Pulmicort Respules(R) (budesonide inhaled solution). In conjunction with the Court's Order against Teva, AstraZeneca agreed and that it too would halt all sales of its authorized generic budesonide inhalation suspension product and take other necessary steps to comply with the Court's decision. Par is the licensed distributor for AstraZeneca's authorized generic version of PULMICORT RESPULES.

The TRO remains in force until further notice by the Court. This action does not effect sales of branded Pulmicort Respules

About Par Pharmaceutical

Par Pharmaceutical, Inc. develops, manufactures and markets generic drugs and innovative branded pharmaceuticals for specialty markets. For press release and other company information, visit www.parpharm.com.

SafeHarbor Statement

Certain statements in this news release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. To the extent any statements made in this news release contain information that is not historical, these statements are essentially forward-looking and, as such, are subject to known and unknown risks, uncertainties and contingencies, many of which are beyond the control of the Company, which could cause actual results and outcomes to differ materially from those expressed herein. Risk factors that might affect such forward-looking statements include those set forth in Item 1A of the Company's Annual Report on Form 10-K for the year ended December 31, 2007, in Item 1A of the Company's subsequent Quarterly Reports on Form 10-Q, in other of the Company's filings with the SEC from time to time, including Current Reports on Form 8-K, and on general industry and economic conditions. Any forward-looking statements included in this news release are made as of the date hereof only, based on information available to the Company as of the date hereof, and, subject to any applicable law to the contrary, the Company assumes no obligation to update any forward-looking statements.


'/>"/>
SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. WWMR Announces Pain Clinic Physicians Most Appreciated Companies: Pfizer, Eli Lilly and Endo Pharmaceuticals
2. PacificGMP and Actinium Pharmaceuticals Announce Agreements for cGMP Antibody Manufacturing and Stability Testing
3. Jazz Pharmaceuticals Cancels Presentation Planned for November 19, 2008 at Lazard Capital Markets 5th Annual Healthcare Conference
4. MiddleBrook Pharmaceuticals Hires Key Commercial Team Members
5. Benda Pharmaceutical Reports Third Quarter 2008 Financial Results
6. Anadys Pharmaceuticals to Present at the Needham Focus on Infectious Disease Conference
7. Savient Pharmaceuticals to Present at the Lazard Capital Markets 5th Annual Healthcare Conference on November 18th
8. Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results
9. ISTA Pharmaceuticals Files New Drug Application with U.S. FDA for Bepreve(TM)
10. NanoBio to Give Four Scientific Presentations at Upcoming National Meeting of Pharmaceutical Scientists
11. Memory Pharmaceuticals Reports Third Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... light to control cells — optogenetics — is key to exciting advances in ... the art, spatially patterned light projected via free-space optics stimulates small, transparent organisms ...
(Date:12/8/2016)... BARCELONA, Spain , Dec. 8, 2016  Anaconda ... on the development of the next generation neuro-thrombectomy system ... the appointment of Tudor G. Jovin, MD to join ... to serve as a strategic network of scientific and ... progresses the development of the ANCD BRAIN ® ...
(Date:12/8/2016)... ... December 08, 2016 , ... This CAST literature review ... biotech crops. The authors focus on the economic effects in countries that are major ... new biotech crops and the resultant risk of low level presence (LLP) puts large ...
(Date:12/8/2016)... HOWELL, N.J. , Dec. 8, 2016 /PRNewswire/ ... aquatic augmentation remediation technologies and selected NewTechBio,s NT-MAX ... , a microbial based beneficial bacteria, in conjunction ... Inc., to correct deficiencies with National Pollutant Discharge ... basin 281-8H has experienced a steady history of ...
Breaking Biology Technology:
(Date:12/7/2016)... Israel , December 7, 2016 BioCatch ... the expansion of its patent portfolio, which grew to over 40 granted ... , , ... its recently filed patent entitled " System, Device, and Method ... technology that enables device makers to forego costly hardware components needed to ...
(Date:12/6/2016)... N.C. , Dec. 6, 2016 Valencell ... announced today it has seen a third consecutive year ... biometric sensor technology in 2016 with a 360 percent ... last year. This increase was driven by sales of ... as robust interest in its technology for hearables for ...
(Date:12/2/2016)... Dec. 1, 2016   SoftServe , a ... BioLock , an electrocardiogram (ECG) biosensor analysis system ... key IoT asset. The smart system ensures device-to-device ... steering wheel and mobile devices to easily ,recognize, ... As vehicle technology advances, so too must ...
Breaking Biology News(10 mins):